Evidence map›Paper›PMID 36633787›Full record

SynthesisBiological trace element research2023

Circulating Copper and Liver Cancer.

Weiwei Chen, Zhiwei Zhang, Ke Liu, Die Jiang, Xiaohui Sun, Yingying Mao, Songtao Li, Ding Ye

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Biological trace element research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Weiwei ChenSchool of Public Health, Zhejiang Chinese Medical University, Binwen Road 548, Hangzhou, 310053, Zhejiang, China.
Zhiwei ZhangThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Ke LiuSchool of Public Health, Zhejiang Chinese Medical University, Binwen Road 548, Hangzhou, 310053, Zhejiang, China.
Die JiangSchool of Public Health, Zhejiang Chinese Medical University, Binwen Road 548, Hangzhou, 310053, Zhejiang, China.
Xiaohui SunSchool of Public Health, Zhejiang Chinese Medical University, Binwen Road 548, Hangzhou, 310053, Zhejiang, China.
Yingying MaoSchool of Public Health, Zhejiang Chinese Medical University, Binwen Road 548, Hangzhou, 310053, Zhejiang, China.
Songtao Li *School of Public Health, Zhejiang Chinese Medical University, Binwen Road 548, Hangzhou, 310053, Zhejiang, China. lisongtao@zcmu.edu.cn.
Ding Ye *School of Public Health, Zhejiang Chinese Medical University, Binwen Road 548, Hangzhou, 310053, Zhejiang, China. yeding@zcmu.edu.cn.
Zhejiang Chinese Medical University · CN

Funding

Natural Science Foundation of Zhejiang Province LQ20H260008Zhejiang Chinese Medical University Foundation 2020ZG01
6 · The paper itself

Abstract

The association between circulating copper and the risk of liver cancer has been investigated by previous studies, while the findings were inconsistent. Thus, we aimed to evaluate the association between circulating copper and liver cancer by using meta-analysis and Mendelian randomization (MR). For meta-analysis, PubMed and Web of Science were searched to identify eligible studies published before April 4, 2022. Standardized mean difference (SMD) with 95% confidence interval (CI) in circulating copper level between liver cancer patients and controls were pooled. Furthermore, we selected genetic instruments for circulating copper from a genome-wide association study (GWAS) to conduct MR analysis. The summary statistics related to liver cancer were obtained from two large independent cohorts, UKBB and FinnGen, respectively. MR analysis was performed mainly by inverse-variance weighted (IVW) approach, followed by maximum-likelihood method as sensitivity analysis. In meta-analysis of eight studies, circulating copper was found to be higher in liver cancer patients (SMD: 1.65; 95% CI: 0.65 to 2.65) with high heterogeneity (I

Indexed as

Genome-Wide Association StudyLiver NeoplasmsCopperHumansPolymorphism, Single NucleotideCopperCirculating copperLiver cancerMendelian randomization analysisMeta-analysis

Identifiers

PMID36633787
OpenAlexW4315703407

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.